Matthew Goldberg, M.D. has served as Castle Biosciences’ Medical Director since August 2020. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Before joining the Mount Sinai faculty, he directed Dermatopathology education for the MedStar Georgetown/Washington Hospital Center dermatology residency program. Dr. Goldberg has a background in translational melanoma research and received the Dermatology Foundation Dermatopathology Research Career Development Award for his research in the field of melanoma epigenetics.Dr. Goldberg graduated summa cum laude from Princeton University and received his medical degree from the Icahn School of Medicine at Mount Sinai. Dr. Goldberg completed his dermatology residency at the University of California, San Francisco, and completed a dermatopathology fellowship at the University of Texas Southwestern. Dr. Goldberg is board certified in dermatology and dermatopathology.
Using Molecular Diagnostics to Inform Cancer Management Decisions
Advanced approaches in molecular diagnostics can provide independent prognostic information to help clinicians make more informed decisions in the care of their patients, when limited information is available. This discussion will explore the use of genomics and spatialomics to guide personalized care in the management of skin cancers and Barrett's esophagus.
Track Chair: Hakan Sakul, Pfizer